The Indian pharmaceutical industry remains robust in spite of potential trade challenges as U.S. President Donald Trump considers imposing tariffs on medication imports. Industry specialists are assured that Indian pharmaceutical firms will retain th
According to Marksans Pharma, its subsidiary company, Relonchem, has received marketing authorization for...
The Indian pharmaceutical market climbed to a year-on-year growth of 8.4% in January 2025, finding its feet with the assistance of...
The pharmaceutical enterprises in India to expand their market beyond the United States, as Trump administration proposed a tariff of...
US biopharma Amgen is allocating USD 200 million this year for its new facility in the region and intends to make substantial investments in the upcoming years, stated CEO Robert Bradway on Monday.
During intraday trading on Monday, GlaxoSmithKline Pharmaceuticals saw its share price shoot up by 5% to Rs 2,640 on the BSE, with a three-month high. The BSE Sensex dropped by...
Pharmaceutical industry Cipla has obtained final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) it submitted for ‘Nilotinib Capsules 50, 150, and 200 mg’...
On February 19, pharmaceutical stocks faced pressure after remarks from US President Donald Trump, indicating that the US could implement tariffs close to 25% on imports of pharmaceuticals, automobiles, and semiconductors...
The maximum retail price (MRP) of medications and formulations that are no longer subject to customs duty has been adjusted by the National Pharmaceutical Pricing Authority (NPPA) in accordance with this year's budget.
In the context of ongoing US-India discussions on tariffs, key pharmaceutical industry bodies in India—Pharmaceuticals Exports Promotion Council (Pharmexcil), Indian Pharmaceutical Association (IPA), and Indian Drug Manufacturers Association (IDMA...
.jpg)
, CDSCO.jpg)